-transparent.png){kind=logo}
The antitumor activity of Carbetimer was tested against 171 patient's tumors in a human tumor cloning system. Sixty-seven tumor specimens had adequate growth to be considered evaluable. In 21 specimens survival of tumor colony forming units was less than or equal to 50% that in control plates. Antitumor effect was most impressive in carcinomas of the breast, ovary, and lung. This information will be useful in planning disease oriented Phase II trials.
Related Publications
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
May 1981,
Cancer research,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
January 1982,
Cancer chemotherapy and pharmacology,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
January 1984,
Cancer drug delivery,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
January 1983,
Investigational new drugs,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
January 1983,
Cancer,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
November 1987,
European journal of cancer & clinical oncology,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
April 1983,
Cancer research,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
January 1989,
Cancer chemotherapy and pharmacology,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
August 1982,
Cancer,
D L Kisner, and
P Mehta, and
G E Paget, and
D D Von Hoff
April 1983,
International journal of cell cloning,
